CD8A and neoplasm: As a result, GB4-BPL@siCXCR2/pPTEN treatment increased the M1/M2 ratio of macrophages, the proportion of CD3+CD8+ T lymphocytes, and the frequency of NK cells in tumor tissues, highlighting the great potential of GB4-BPL@siCXCR2/pPTEN to increase antitumor immunity (Figure 7H, S21-S25).